| Study Period | 2019 - 2032 |
| Market Size in 2024 | USD 3.9 Billion |
| Market Size in 2025 | USD 4.5 Billion |
| Market Size by 2032 | USD 12.0 Billion |
| Projected CAGR | 15.2% |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Market Structure | Semi-consolidated |
Explore the market potential with our data-driven report
The bioanalytical testing services market size was USD 3.9 billion in 2024, and it will grow by 15.2% during 2025–2032, to reach USD 12.0 billion by 2032.
The robust growth of the market is primarily driven by the increasing complexity of drug development pipelines, particularly for biologics and biosimilars, coupled with the rising trend of outsourcing analytical testing services to specialized contract research organizations. The pharmaceutical and biotechnology industries are witnessing unprecedented growth in the development of complex therapeutic modalities, including monoclonal antibodies, gene therapies, and cell-based treatments.
This surge in biologics development has created substantial demand for specialized bioanalytical testing services that can handle the unique challenges associated with large molecule analysis, including protein characterization, immunogenicity assessment, and stability testing. The trend of outsourcing bioanalytical testing activities is driven by the need to reduce capital investments in sophisticated analytical equipment, access specialized expertise, and accelerate time-to-market for new therapeutics. This is attributed to the established life sciences industry utilizing bioanalytical testing, the presence of key service providers, the increased number of ongoing clinical trials, high research and development expenditure, and the expansion of biosimilar and generic markets.
Moreover, the increasing preference of key players toward analytical testing of biosimilars and biologics, the rising healthcare spending for providing improved health services, and the surging focus of industry players on the approvals and launches of testing services during crucial times are boosting the market demand. In addition, the rising prevalence of infectious and chronic diseases and government policies to control the outbreaks of infectious diseases, such as COVID-19 and HIV, is expected to provide more opportunities to utilize these testing services for the detection of diseases, which, in turn, leads to the growth of the market.
The small category held the larger market share, of approx. 65%, in 2024, because small molecules are traditional pharmaceuticals, and typically they have a low molecular weight of less than 900 Daltons and regulate a biological process. Moreover, many outsourcing companies are offering studies on many small molecules, such as pharmacokinetic studies, pharmacodynamic studies, and assays of biomarkers. For example, XenoTech LLC, a subsidiary of BiolVT LLC, offers analytical services including high-performance liquid chromatography with mass spectrometry, different detectors, and ultraviolet-visible spectroscopy to various non-regulated small molecule bioanalysis, to determine a precise measurement of metabolite concentration and/or parent drug in various biological matrices to help absorption, distribution, metabolism, and excretion, drug-drug interaction, and drug metabolism and pharmacokinetics studies in drug development.
In addition, many branded and generic compounds are typically small molecules. Also, manufacturers have to conduct and give reports of bioanalytical testing, due to the rising patent expiration. Thus, this factor boosts the acceptance of bioanalytical testing for small molecules.
The large category will have the higher CAGR, because many biologics or amino acid-based molecules are under development. Moreover, the testing of these molecules needs advanced techniques, improved infrastructure, and new-generation analytical instruments, which are mainly accessible with bioanalytical service providers. The analytical complexity of large molecules, requiring sophisticated techniques, such as intact mass analysis, peptide mapping, and higher-order structure characterization, drives demand for specialized bioanalytical services.
In 2024, the U.S. FDA approved 16 biologics, reflecting steady innovation in biopharmaceuticals. Moreover, in the first half of 2025, combined FDA and EMA approvals included around 49 additional products—comprising 29 biologics and 16 biosimilars—many of which were indication expansions, with at least 6 being newly approved biologic entities.
The molecule types analyzed in this report are:
The bioavailability category held the largest market share, of about 35%, in 2024. This is attributed to the high demand for these services in generic molecule development. Moreover, companies are more focused on producing the best effective therapeutic drugs with an effective drug moiety. Additionally, the rising consumer concern about self-care is boosting the consumption of pharmaceutical drugs, which, in turn, significantly drives the demand for bioavailability testing.
The bioequivalence category will have the highest CAGR, due to the surging demand for generic drugs and biosimilars, driven by patent expirations of branded medicines and cost-effective treatment needs. Regulatory agencies mandate strict bioequivalence studies for approval, fueling outsourcing to specialized CROs.
The test types analyzed in this report are:
The pharmaceutical & biopharmaceutical companies category held the largest market share in 2024. This is because these companies are mainly focused on the development of new drugs for the treatment of various diseases, and are also more concentrated on the mass manufacturing of drugs due to the rising prevalence of diseases and many infectious cases. So, the companies are adopting outsourcing of the early-phase development of drug, laboratory, and clinical testing services to improve profit margins, avoid high expenditure, and reduce time to validate the products and processes.
The contract research organizations category will have the highest CAGR, because CROs are helping pharmaceutical companies to cater to the need for pharmaceutical products, and many organizations are encouraging in-house tests and intensifying test capabilities in several places.
The end users analyzed in this report are:
The sample analysis category held the largest market share, of about 65%, in 2024, and it will have the highest CAGR, because sample analysis has played a key role in the process of drug development. This workflow aids in identifying impurities present in a sample and checking the stability of drug molecules. Thus, the surging rate of drug development is a major factor driving the need for sample analysis.
Moreover, finding the assays of molecules comes under the sample analysis. Assay finding is a crucial step in the drug development process, and services offered by key players for finding the assays on an outsourcing basis drive the market in this category.
The workflows analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America held the largest market share in 2024. This is attributed to the existence of a large number of patients with chronic diseases, the rise in the acceptance of large molecule therapeutics and peptides, significant growth in the pharmaceutical and biotechnical industries, and the presence of major service providers for bioanalytical services in the region.
The U.S. leads the North American market due to the presence of advanced healthcare infrastructure, a large number of pharmaceutical manufacturing facilities, and major contract research organizations and service providers of bioanalytical testing in the country. The U.S. pharmaceutical industry's substantial R&D investments continue to drive regional market growth. This high level of investment directly fuels demand for bioanalytical testing services across all stages of drug development, from early discovery through post-marketing surveillance.
The region benefits from a mature outsourcing ecosystem where pharmaceutical companies have established strategic partnerships with bioanalytical testing service providers. Additionally, the FDA's stringent regulatory requirements for bioanalytical method validation, as outlined in the ICH M10 guideline, ensure consistent demand for high-quality bioanalytical services that meet regulatory standards.
Asia-Pacific will have the highest CAGR. This growth can be mainly driven by the rising demand for pharmaceutical outsourcing services, the increasing clinical trial activities to save costs, the presence of a large population, the retention of clinical trial participants, the constant improvement in regulatory procedures, and the rising focus on drug R&D initiatives in the region. In APAC, the Chinese market shows significant growth, due to the increasing drug innovation and development activities, the presence of a large patient pool, the prevalence of chronic and infectious diseases, and the surging adoption of pharmaceutical outsourcing for bioanalytical testing services, in the country.
The rapid transformation of China’s pharmaceutical market has established the country as a major growth driver within the Asia-Pacific region. The R&D expansion has created substantial demand for bioanalytical testing services, particularly as Chinese pharmaceutical companies pursue global drug development programs requiring internationally accepted analytical standards.
India's emergence as a global hub for bioanalytical testing services is noteworthy, with the country offering a compelling combination of scientific expertise, cost advantages, and regulatory compliance capabilities. According to the Indian Pharmaceutical Alliance, India's pharmaceutical sector is expected to reach USD 130 billion by 2030, with bioanalytical services representing a high-growth segment. The country's established presence in generic drug manufacturing creates consistent demand for bioequivalence testing services, while its growing biosimilar industry drives adoption of advanced bioanalytical techniques for large molecule characterization.
The European bioanalytical testing services market accounts for the second-largest revenue share. This is attributed to the rising amount of investment by pharmaceutical and biotechnology companies in R&D activities, the increasing cases of chronic diseases, and a large number of contract manufacturing and research organizations utilizing bioanalytical testing in the region.
Germany leads the European market, owing to its promotion of in-house testing facilities for bioanalytical testing, expanding test facilities, and companies being more focused on outsourcing testing services in the country. On the other hand, the market in France shows significant growth, due to companies expanding their projects for providing bioanalytical contract solutions.
The geographical breakdown of the market is as follows:
The market is semi-consolidated and characterized by the presence of established global contract research organizations, specialized bioanalytical service providers, and emerging regional players. Leading market participants have adopted diverse competitive strategies to strengthen their market positions. Charles River Laboratories International, IQVIA, and SGS SA have pursued aggressive acquisition strategies to expand their bioanalytical capabilities and geographical footprint, reflecting consolidation trends as companies seek to achieve scale. The adoption of high-resolution mass spectrometry, automated sample processing systems, and AI-powered data analysis tools has become a key differentiator. Additionally, companies that integrate these technologies while maintaining regulatory compliance are better positioned to capture market share.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages